WFG Advisors’s VanEck Biotech ETF BBH Stock Holding History

WFG Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$6K	Sell	49 -37	-43%	-$4.46K	﹤0.01%	1238
2017 Q1	$10K	Sell	86 -100	-54%	-$11.7K	﹤0.01%	1066
2016 Q4	$20K	Sell	186 -100	-35%	-$10.9K	﹤0.01%	935
2016 Q3	$33K	Hold	286	–	–	0.01%	805
2016 Q2	$29K	Buy	+286	New	+$30.5K	0.01%	832
2016 Q1	–	Sell	-100	Closed	-$13K	–	1533
2015 Q4	$13K	Hold	100	–	–	﹤0.01%	1009
2015 Q3	$11K	Hold	100	–	–	﹤0.01%	1061
2015 Q2	$13K	Hold	100	–	–	﹤0.01%	1102
2015 Q1	$13K	Sell	100 -60	-38%	-$7.54K	﹤0.01%	1115
2014 Q4	$18K	Buy	160 +100	+167%	+$11.3K	﹤0.01%	1254
2014 Q3	$6K	Hold	60	–	–	﹤0.01%	1605
2014 Q2	$6K	Hold	60	–	–	﹤0.01%	1599
2014 Q1	$5K	Buy	+60	New	+$5.83K	﹤0.01%	1609

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return

WFG Advisors's BBH Position: Q2 2017 in Review

WFG Advisors reduced its VanEck Biotech ETF (BBH) stake by 43% in Q2 2017, selling an estimated $4.46K and leaving 49 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

WFG Advisors first reported a position in BBH in Q1 2014 and has held it in 13 quarters since. The position peaked at $33K in Q3 2016. 83 funds tracked by Wall St. Rank hold BBH as of Q2 2017.

WFG Advisors held 49 shares of VanEck Biotech ETF worth $6K as of Q2 2017.
WFG Advisors sold 37 VanEck Biotech ETF shares in Q2 2017, an estimated $4.46K.
VanEck Biotech ETF made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1238 holding.
WFG Advisors first reported a position in VanEck Biotech ETF in Q1 2014 and has held it in 13 quarters since.
WFG Advisors's VanEck Biotech ETF position peaked at $33K in Q3 2016.
83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.